- Home
- PVLA vs BTAI Comparison
PVLA vs BTAI Comparison
Compare PVLA & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- BTAI
- Stock Information
- Founded
- PVLA 2015
- BTAI 2017
- Country
- PVLA United States
- BTAI United States
- Employees
- PVLA N/A
- BTAI N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- PVLA Health Care
- BTAI Health Care
- Exchange
- PVLA Nasdaq
- BTAI Nasdaq
- Market Cap
- PVLA 15.9M
- BTAI 18.1M
- IPO Year
- PVLA N/A
- BTAI 2018
- Fundamental
- Price
- PVLA $13.15
- BTAI $0.36
- Analyst Decision
- PVLA Strong Buy
- BTAI Buy
- Analyst Count
- PVLA 1
- BTAI 4
- Target Price
- PVLA $38.00
- BTAI $2.81
- AVG Volume (30 Days)
- PVLA 39.6K
- BTAI 1.3M
- Earning Date
- PVLA 02-15-2025
- BTAI 03-11-2025
- Dividend Yield
- PVLA N/A
- BTAI N/A
- EPS Growth
- PVLA N/A
- BTAI N/A
- EPS
- PVLA N/A
- BTAI N/A
- Revenue
- PVLA N/A
- BTAI $2,276,000.00
- Revenue This Year
- PVLA N/A
- BTAI $131.45
- Revenue Next Year
- PVLA N/A
- BTAI $45.65
- P/E Ratio
- PVLA N/A
- BTAI N/A
- Revenue Growth
- PVLA N/A
- BTAI 83.25
- 52 Week Low
- PVLA $6.20
- BTAI $0.30
- 52 Week High
- PVLA $22.32
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- BTAI 45.04
- Support Level
- PVLA N/A
- BTAI $0.33
- Resistance Level
- PVLA N/A
- BTAI $0.39
- Average True Range (ATR)
- PVLA 0.00
- BTAI 0.06
- MACD
- PVLA 0.00
- BTAI -0.00
- Stochastic Oscillator
- PVLA 0.00
- BTAI 16.80
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.